Liraglutide eases sleep‑apnoea in trial

Obstructive sleep apnea is what happens when the throat keeps collapsing during sleep, like a soft straw pinching shut over and over, and doctors track it with the apnea-hypopnea index, which counts breathing interruptions per hour. Obesity raises the odds because extra tissue around the neck and chest can make the airway narrower and breathing harder at night. (wiley.com) Chronic obstructive pulmonary disease is a separate lung disease that makes it hard to move air in and out, usually because the airways are damaged and inflamed. When chronic obstructive pulmonary disease and obstructive sleep apnea show up together, studies link the combination to higher illness and death than either condition alone. (wiley.com) Liraglutide is a glucagon-like peptide 1 drug, which means it mimics a gut hormone that tells the brain you have eaten and slows stomach emptying. In practice, that usually cuts appetite and body weight, which is why liraglutide has been used for obesity and diabetes. (wiley.com) That weight-loss link is why sleep doctors started paying attention years ago. In a 359-person randomized trial published in 2016, liraglutide 3.0 milligrams cut the apnea-hypopnea index by 12.2 events per hour versus 6.1 with placebo after 32 weeks in people with obesity and moderate or severe obstructive sleep apnea. (nature.com) The new result goes after a narrower and sicker group: people with overweight or obesity who also had chronic obstructive pulmonary disease. In the Danish randomized trial, 40 participants from two outpatient clinics were assigned to liraglutide 3.0 milligrams by injection or placebo for 40 weeks. (wiley.com) Sleep apnea turned out to be extremely common in that group before treatment even started. The researchers found obstructive sleep apnea in 84% of participants, including 70% of the liraglutide group and 85% of the placebo group at baseline. (wiley.com) By the end of treatment, liraglutide lowered the apnea-hypopnea index by a baseline-adjusted 9.87 events per hour versus placebo. It also lowered the oxygen desaturation index, which counts how often blood oxygen drops during sleep, by 10.16 events per hour. (wiley.com) Patients did not report a statistically significant change on the Epworth Sleepiness Scale, which is a questionnaire about daytime drowsiness. But two Short Form-36 quality-of-life areas, general health perception and role physical, did improve with liraglutide versus placebo. (wiley.com) This was a secondary analysis, which means the original trial was built to study respiratory effects in chronic obstructive pulmonary disease rather than sleep apnea as the main target. That makes the finding more of a strong signal than a final verdict, especially with only 40 participants. (wiley.com) It also fits a bigger shift around these drugs. A 2025 meta-analysis in Sleep Medicine Reviews said glucagon-like peptide 1 receptor agonists improved obstructive sleep apnea measures, while a 2025 network meta-analysis in Chest compared several drugs in the class for the same problem. (sciencedirect.com) (journal.chestnet.org) So the story here is not that a weight-loss shot suddenly became a sleep machine. It is that a drug built to reduce eating may also ease nighttime airway collapse in one of the hardest-to-treat groups: people carrying extra weight while living with damaged lungs. (wiley.com)